Clinical Trial Update: Study Evaluating Treatment of Sacituzumab-govitecan for Patients With Metastatic Esophagogastric Adenocarcinoma [Phase 1, Phase 2]

View source ↗

Summary

This update reports the completion of a Phase 1/2 clinical trial evaluating sacituzumab govitecan for metastatic esophagogastric adenocarcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophagogastric Adenocarcinoma

Drugs mentioned

• Sacituzumab Govitecan (sacituzumab govitecan)

Snippet

Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Conditions: Esophagogastric Adenocarcinoma | Phase 1, Phase 2 | Status: COMPLETED